Inovio Pharmaceuticals (NASDAQ:INO) Raised to “Sell” at StockNews.com

Inovio Pharmaceuticals (NASDAQ:INO) was upgraded by investment analysts at StockNews.com to a “sell” rating in a research note issued to investors on Friday.

A number of other brokerages also recently issued reports on INO. Royal Bank of Canada cut their target price on Inovio Pharmaceuticals from $6.00 to $5.00 and set a “sector perform” rating for the company in a research note on Wednesday. JMP Securities reissued a “market outperform” rating and issued a $18.00 price objective on shares of Inovio Pharmaceuticals in a report on Friday, January 10th. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $3.00 target price on shares of Inovio Pharmaceuticals in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $12.20.

Inovio Pharmaceuticals Stock Down 1.0 %

Shares of NASDAQ INO opened at $1.92 on Friday. The firm has a 50-day simple moving average of $2.04 and a 200-day simple moving average of $3.69. The stock has a market capitalization of $50.11 million, a price-to-earnings ratio of -0.48 and a beta of 0.92. Inovio Pharmaceuticals has a 52 week low of $1.74 and a 52 week high of $14.75.

Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings data on Tuesday, March 18th. The biopharmaceutical company reported ($0.69) EPS for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.18. The business had revenue of $0.12 million during the quarter, compared to analyst estimates of $0.03 million. As a group, equities research analysts expect that Inovio Pharmaceuticals will post -4.23 EPS for the current year.

Institutional Trading of Inovio Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of INO. Deep Track Capital LP increased its position in shares of Inovio Pharmaceuticals by 72.9% during the fourth quarter. Deep Track Capital LP now owns 3,119,162 shares of the biopharmaceutical company’s stock valued at $5,708,000 after acquiring an additional 1,314,796 shares during the last quarter. Stonepine Capital Management LLC acquired a new stake in Inovio Pharmaceuticals in the 4th quarter valued at approximately $1,922,000. AIGH Capital Management LLC acquired a new stake in Inovio Pharmaceuticals in the 4th quarter valued at approximately $1,197,000. Bank of America Corp DE raised its position in Inovio Pharmaceuticals by 1,035.2% in the fourth quarter. Bank of America Corp DE now owns 640,987 shares of the biopharmaceutical company’s stock valued at $1,173,000 after purchasing an additional 584,521 shares during the period. Finally, Geode Capital Management LLC lifted its stake in Inovio Pharmaceuticals by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 628,505 shares of the biopharmaceutical company’s stock worth $1,150,000 after purchasing an additional 6,874 shares in the last quarter. 26.79% of the stock is owned by institutional investors and hedge funds.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.